[HTML][HTML] Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer

J Kang, F La Manna, F Bonollo, N Sampson, IL Alberts… - Cancer letters, 2022 - Elsevier
During disease progression from primary towards metastatic prostate cancer (PCa), and in
particular bone metastases, the tumor microenvironment (TME) evolves in parallel with the …

[HTML][HTML] The fight against cancer by microgravity: The multicellular spheroid as a metastasis model

D Grimm, H Schulz, M Krüger… - International Journal of …, 2022 - mdpi.com
Cancer is a disease exhibiting uncontrollable cell growth and spreading to other parts of the
organism. It is a heavy, worldwide burden for mankind with high morbidity and mortality …

Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms

H Tukachinsky, RW Madison, JH Chung… - Clinical Cancer …, 2021 - AACR
Purpose: Comprehensive genomic profiling (CGP) is of increasing value for patients with
metastatic castration-resistant prostate cancer (mCRPC). mCRPC tends to metastasize to …

Impact of the site of metastases on survival in patients with metastatic prostate cancer

G Gandaglia, PI Karakiewicz, A Briganti, NM Passoni… - European urology, 2015 - Elsevier
Background Limited data exist on the impact of the site of metastases on survival in patients
with stage IV prostate cancer (PCa). Objective To investigate the role of metastatic …

Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years

N Suardi, G Gandaglia, A Gallina, E Di Trapani… - European urology, 2015 - Elsevier
Abstract Background Prostate cancer (PCa) patients with lymph node recurrence after
radical prostatectomy (RP) are usually managed with androgen-deprivation therapy. Despite …

[HTML][HTML] PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer

AD Combes, CA Palma, R Calopedos, L Wen, H Woo… - Diagnostics, 2022 - mdpi.com
Prostate cancer is the most common cancer and the second leading cause of cancer death
in men. The imaging assessment and treatment of prostate cancer has vastly improved over …

Accelerating precision medicine in metastatic prostate cancer

J Mateo, R McKay, W Abida, R Aggarwal, J Alumkal… - Nature cancer, 2020 - nature.com
Despite advances in the screening and treatment of prostate cancer, the therapy options
available, particularly for later stages of the disease, remain limited, and the treatment …

[HTML][HTML] The nerve growth factor-delivered signals in prostate cancer and its associated microenvironment: When the dialogue replaces the monologue

M Di Donato, P Giovannelli, A Migliaccio, G Castoria - Cell & Bioscience, 2023 - Springer
Prostate cancer (PC) represents the most diagnosed and the second most lethal cancer in
men worldwide. Its development and progression occur in concert with alterations in the …

68Ga-PSMA PET/CT replacing bone scan in the initial staging of skeletal metastasis in prostate cancer: a fait accompli?

T Lengana, IO Lawal, TG Boshomane… - Clinical genitourinary …, 2018 - Elsevier
Purpose 68 Ga ligands targeting prostate-specific membrane antigen (PSMA) are rapidly
emerging as a significant step forward in the management of prostate cancer. PSMA is a …

Prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer: an update on important pitfalls

S Sheikhbahaei, RA Werner, LB Solnes… - Seminars in nuclear …, 2019 - Elsevier
The continuing adoption of prostate specific membrane antigen (PSMA)-targeted PET for
prostate cancer molecular imaging requires imagers and clinicians alike to be aware of the …